ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,674 SEK | +1.19% |
|
-1.09% | +23.53% |
| Jun. 13 | Tesla, Inc. : Musk moves a step closer to the $56 billion prize and the transfer of Tesla's headquarters to Texas |  |
| Jun. 13 | AstraZeneca: Farxiga approved for diabetes as of age 10 | CF |
| Sales 2024 * | 51.68B 544B | Sales 2025 * | 55.58B 585B | Capitalization | 245B 2,580B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.79B 92.49B | Net income 2025 * | 10.45B 110B | EV / Sales 2024 * | 5.14 x |
| Net Debt 2024 * | 20.47B 215B | Net Debt 2025 * | 13.93B 147B | EV / Sales 2025 * | 4.66 x |
| P/E ratio 2024 * |
27.8
x | P/E ratio 2025 * |
23.6
x | Employees | 89,900 |
| Yield 2024 * |
1.95% | Yield 2025 * |
2.05% | Free-Float | 96.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +1.16% | ||
| 1 week | -0.95% | ||
| Current month | +1.92% | ||
| 1 month | +0.33% | ||
| 3 months | +20.99% | ||
| 6 months | +22.99% | ||
| Current year | +23.72% |
1 week
1 643.50
1 698.50
1 month
1 608.001 698.50
Current year
1 261.001 698.50
1 year
1 261.001 698.50
3 years
960.301 698.50
5 years
707.001 698.50
10 years
447.501 698.50
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Director/Board Member | 68 | 99-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 1,672 | +1.06% | 71 857 |
| 24-06-13 | 1,654 | +0.12% | 592,800 |
| 24-06-12 | 1,652 | -0.60% | 194,053 |
| 24-06-11 | 1,662 | -1.63% | 209,209 |
| 24-06-10 | 1,690 | -0.06% | 204,621 |
Delayed Quote Nasdaq Stockholm, June 14, 2024 at 05:24 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.1
USD
Average target price
174.4
USD
Spread / Average Target
+10.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.54% | 795B | |
| -7.20% | 350B | |
| +18.67% | 328B | |
| +7.48% | 294B | |
| +1.39% | 222B | |
| +11.38% | 215B | |
| +3.64% | 160B | |
| -3.96% | 157B | |
| -1.69% | 118B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
